1. Acute Kidney Injury after Administering Dapagliflozin to a Diabetic Patient with Acute Cerebral Infarction
- Author
-
김소미 ( So Mi Kim ), 조종태 ( Jong Tae Cho ), 이은경 ( Eun Kyoung Lee ), 전지현 ( Ji Hyun Jeon ), 이지은 ( Ji-eun Lee ), 이도현 ( Do Hyun Lee ), and 박창현 ( Changhyun Park )
- Subjects
medicine.medical_specialty ,Proteinuria ,biology ,business.industry ,Urology ,Acute kidney injury ,Renal function ,medicine.disease ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,chemistry ,Enzyme inhibitor ,Heart failure ,Hypovolemia ,medicine ,biology.protein ,030211 gastroenterology & hepatology ,medicine.symptom ,Dapagliflozin ,SGLT2 Inhibitor ,business - Abstract
Dapagliflozin is a recently developed oral anti-diabetic drug and SGLT2 inhibitor with well-known cardioprotective and renoprotective effects. Although a reduction of the glomerular filtration rate is induced by volume depletion and tubule-glomerular feedback during the early period after administering a SGLT2 inhibitor, the renal prognosis improves more with a decrease of proteinuria. However, the risk of acute kidney injury increases in heart failure and hypovolemia patients, and in those taking certain drugs, such as non-steroidal anti-inflammatory drugs, angiotensin-converting enzyme inhibitor/angiotensin II receptor blockers, or diuretics. We report acute kidney injury after dapagliflozin administration in a diabetic patient with acute cerebral infarction accompanied by right hemiplegia, motor aphasia, and dysphagia. (Korean J Med 2020;95:404-408)
- Published
- 2020
- Full Text
- View/download PDF